Ivermectin Not Effective in Stopping Severe COVID, Study Finds
February 22, 2022 – Controversial antiparasitic drug ivermectin fails to treat mild to moderate COVID-19, another new study found.
“The results of the study do not support the use of ivermectin for patients with COVID-19,” the researchers said in a study published last week in JAMA Internal Medicine. The trial took place at 20 public hospitals and a COVID-19 quarantine center in Malaysia from May 31 to October 25. Among 241 patients treated with ivermectin, 52 developed severe COVID-19 compared with 43 of 249 patients who did not take the drug.
The study subjects, with a mean age of 62 years and representing 55% of women, were randomly assigned to receive either a 5-day course of ivermectin plus standard therapy or standard therapy alone.
No difference in vaccine status
The researchers also looked at small groups of people in the study to see if there were differences in whether they were vaccinated. They said the analysis was “undistinguished.”
Just over half of the participants (51.8%) were fully vaccinated with two doses of COVID-19 vaccines. Among vaccinated patients, 17.7% in the ivermectin group and 9.2% in the control group developed severe disease.
Ivermectin and COVID
Although the FDA has not approved ivermectin for the treatment of COVID-19, doctors still continue to prescribe an inexpensive and widely available antiparasitic drug. There is little evidence that the drug is effective in treating COVID-19, but vaccine advocates have embraced it as a useful alternative. There have been reports of people being hospitalized after taking ivermectin, and the FDA has even warned against its use.
The authors of the new study acknowledge the controversy: “While some early clinical studies suggested the potential efficacy of ivermectin in the treatment and prevention of COVID-19, these studies had methodological flaws.”